Andrew Owen

[Sanjiv Sharma @Sanjiv_BitS]

A warm welcome to Dr Lalitkumar Vora, who is visiting Liverpool to present research on microarray patches at the 25th International Workshop on Clinical Pharmacology. Fantastic workshop! @lalitkvora @sudhaunsh @LivUni @LivUniISMIB @_AndrewOwen_ @CAMO_Net1

[Catriona Waitt @CatrionaWaitt]

I feel quite emotional having listened to @daveback01 summarising 40 years of antiretroviral pharmacology & the history of @pandtuol @LivUni. So much progress to celebrate but also a reminder that people matter more than things. What an inspiration! #AtTheEquatorUG #AntiviralPK

[Catriona Waitt @CatrionaWaitt]

#AntiviralPK challenging and fascinating talk by @aeolagunju on perinatal considerations for long acting medications. Pregnant & breastfeeding women are a major part of society, must not be neglected and we need to harness the very best science to advance knowledge @wellcometrust

[Adeniyi Olagunju @aeolagunju]

You're invited!
Webinar title: "Voluntary licensing & patent pooling for equitable access to life-saving medicines".

To receive joining details, please register here: https://t.co/5kQ7sR55Nq

[Centre of Excellence for Long-acting Therapeutics @CELTLiverpool]

🚨 RECRUITMENT NEWS
We're looking for a #DataCurator from a relevant field, for maintenance of open access platforms tracking global development, patent & regulatory status of #LongActing therapeutics & technologies.
Deadline: 2/2/24.

Find out more here
👉https://t.co/LP8Z8r9rso

[Adeniyi Olagunju @aeolagunju]

Deadline: 02 Feb 2024
You will join an excellent team here @pandtuol @LivUniISMIB, working in collaboration with @Lobnacting & colleagues @MedsPatentPool, and @Long_Acting_HIV.
@_AndrewOwen_

[Adeniyi Olagunju @aeolagunju]

📢We're hiring!
A data curator @CELTLiverpool for further development & maintenance of open access platforms for tracking global development, patent & regulatory status of long-acting therapeutics & technologies.
Details: https://t.co/Xim6K9uVuO

[Johan Neyts @neyts_johan]

Check our paper in ⁦@VirusesMDPI⁩
on a hamster infection model with #SARSCoV2 subvariants BA.2.86 and EG.5.1 (the latter is the parent of the JN sub-variants) ⁦@KU_Leuven⁩ ⁦@SSI_dk⁩ @MDPIOpenAccess
https://t.co/Fo5uPOdGVx
https://t.co/Fo5uPOdGVx

[Andrew Owen @_AndrewOwen_]

@cla_cor It’s been too long Claudia! Where are you?

[Centre of Excellence for Long-acting Therapeutics @CELTLiverpool]

Approximately 75% of people living with #HepatitisC reside in #LMICs with the majority having limited access to life-saving medication.

Find out how the #LONGEVITYProject aims to ease the #HCV burden with #longacting injectable medicines.

👉https://t.co/Scai2brB0p

[Eric Topol @EricTopol]

"It’s important to acknowledge that objectively we are in a better place with regard to the virus than we’ve ever been"
from @today's @NEJM commentary
https://t.co/E08WE0W4Rw

[Inst of Systems, Molecular & Integrative Biology @LivUniISMIB]

We're recruiting for a Mathematical Modeller in Pharmacokinetics for a Medical Research Council funded project.

✅Research the next generation of newly formulated drugs
✅Progress new approaches to therapy
✅Join a multi-disciplinary team

Job spec here: https://t.co/ZoebVKFOmj

[Eric Topol @EricTopol]

Good news: In the Northeast where the XBB.1.5 variant now accounts for >75% cases, hospital admissions among seniors have mostly started to decline
https://t.co/MOQpgmNWGl

[Jacob Trefethen @JacobTref]

New hit-to-lead grants for drugs against malaria, TB, chagas, and visceral leishmaniasis: https://t.co/3Re0mJdhIi

Compounds must come from a Japanese library, partner with @MedsforMalaria, @DNDi, or @TBAlliance. Grants up to 2 years, Intent to Apply deadline = Feb 10th

[The BMJ @bmj_latest]

This nationwide study suggests that patients with mild covid-19 are at risk for a small number of health outcomes, most of which are resolved within a year from diagnosis https://t.co/yjZEIqddPh

[Eric Topol @EricTopol]

Some #SARSCoV2 mutations that confer resistance to Paxlovid have been deposited @NCBI & @GISAID
https://t.co/bzgje9aYqJ @ScienceTM
"Our findings argue for highly selective use...because extensive, unselective use is expected to rapidly lead to emergence of drug resistance."

[World Health Organization (WHO) @WHO]

WHO has issued a rapid risk assessment based on the available data on the Omicron XBB.1.5 variant.
Learn more🔗https://t.co/DJYy7nGYrC

[World Health Organization (WHO) @WHO]

Congratulations 👏🏾 to #Uganda 🇺🇬 for declaring the end of the #Ebola outbreak today, less than four months after the confirmation of the first case.

https://t.co/hRFE6QBm6C